EP 2104R

Drug Profile

EP 2104R

Latest Information Update: 22 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax; EPIX Pharmaceuticals
  • Developer EPIX Pharmaceuticals
  • Class Contrast media; Lanthanoid series elements; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 20 Apr 2010 Intellectual properties pertaining to EP 2104R are being auctioned in the US (http://www.finnwarnkegayton.com)
  • 07 Dec 2006 Final results from a phase IIA clinical trial in Magnetic resonance imaging added to the Diagnostic Agents therapeutic trials section
  • 18 Jul 2006 EP 2104R is available for licensing worldwide (http://www.epixpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top